Healthy Living

FDA Grants Orphan Drug Status for ACE-083 to Treat Muscular Dystrophy

Acceleron hopes that this designation will lead to more groundbreaking treatment options

The company recently released a statement about the drug and where they hope to go with their trials. Future plans include more time for clinical development, as well as the development of the company's compound. Both will hopefully lead to more research and development of groundbreaking treatment options that can help other musculoskeletal disorders. 

Even though the future looks bright, everyone involved in the trials is still remaining cautious. There are many factors that can easily derail the release of ACE-083, like different results in phase 2, a larger budget, and a bigger time-frame.